Center for Diabetes Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.
Department of Clinical Pharmacology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.
Diabetes Obes Metab. 2017 Sep;19(9):1214-1222. doi: 10.1111/dom.12946. Epub 2017 Apr 27.
Bile acids are amphipathic water-soluble steroid-based molecules best known for their important lipid-solubilizing role in the assimilation of fat. Recently, bile acids have emerged as metabolic integrators with glucose-lowering potential. Among a variety of gluco-metabolic effects, bile acids have been demonstrated to modulate the secretion of the gut-derived incretin hormone glucagon-like peptide-1 (GLP-1), possibly via the transmembrane receptor Takeda G-protein-coupled receptor 5 and the nuclear farnesoid X receptor, in intestinal L cells. The present article critically reviews current evidence connecting established glucose-lowering drugs to bile acid-induced GLP-1 secretion, and discusses whether bile acid-induced GLP-1 secretion may constitute a new basis for understanding how metformin, inhibitors of the apical sodium-dependent bile acids transporter, and bile acid sequestrants - old, new and neglected glucose-lowering drugs - improve glucose metabolism.
胆汁酸是一种两亲性水溶性甾体类分子,以其在脂肪吸收中重要的脂质溶解作用而闻名。最近,胆汁酸已成为具有降血糖潜力的代谢调节剂。在各种糖代谢作用中,已证实胆汁酸可通过跨膜受体 Takeda G 蛋白偶联受体 5 和核法尼醇 X 受体调节肠源性肠促胰岛素激素胰高血糖素样肽 1 (GLP-1) 的分泌,可能在肠道 L 细胞中。本文批判性地回顾了将现有的降糖药物与胆汁酸诱导的 GLP-1 分泌联系起来的现有证据,并讨论了胆汁酸诱导的 GLP-1 分泌是否可能构成理解二甲双胍、顶端钠依赖性胆汁酸转运体抑制剂以及胆汁酸螯合剂(旧的、新的和被忽视的降糖药物)如何改善葡萄糖代谢的新基础。